Prostatic urethral lift (UroLift): a real-world analysis of outcomes using hospital episodes statistics

• Published in: BMC urology 2021-04, Vol.21 (1), p.55-55, Article 55
• Main Authors: Page, Toby, Veeratterapillay, Rajan, Keltie, Kim, Burn, Julie, Sims, Andrew
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Analysis; Bladder; BPH; Catheterization; Catheters; Coding standards; Datasets; Demography; Endoscopy; England; Fatalities; Hospitals; Humans; Intervention; Intubation; Lower Urinary Tract Symptoms - surgery; LUTS; Male; Middle Aged; Morbidity; Mortality; Patients; Prostate; Prostate - surgery; Prostatic urethral lift; Prostheses; Retention; Retrospective Studies; Statistical analysis; Statistics; Surgery; Treatment Outcome; Type 2 diabetes; Urethra - surgery; Urinary retention; Urogenital system; UroLift; Urologic Surgical Procedures, Male - methods; Urologic Surgical Procedures, Male - statistics & numerical data; Urology
• ISSN: 1471-2490; 1471-2490
• DOI: 10.1186/s12894-021-00824-5

To determine real-world outcomes of prostatic urethral lift (UroLift) procedures conducted in hospitals across England. A retrospective observational cohort was identified from Hospital Episode Statistics data including men undergoing UroLift in hospitals in England between 2017 and 2020. Procedure uptake, patient demographics, inpatient complications, 30-day accident and emergency re-attendance rate, requirement for further treatment and catheterization were captured. Kaplan-Meier and hazard analysis were used to analyse time to re-treatment. 2942 index UroLift procedures from 80 hospital trusts were analysed; 85.3% conducted as day-case surgery (admitted to hospital for a planned surgical procedure and returning home on the same day). In-hospital complication rate was 3.4%. 93% of men were catheter-free at 30 days. The acute accident and emergency attendance rate within 30 days was 12.0%. Results of Kaplan Meier analysis for subsequent re-treatment (including additional UroLift and endoscopic intervention) at 1 and 2 years were 5.2% [95% CI 4.2 to 6.1] and 11.9% [10.1 to 13.6] respectively. This real-world analysis of UroLift shows that it can be delivered safely in a day-case setting with minimal morbidity. However, hospital resource usage for catheterization and emergency hospital attendance in the first 30 days was substantial, and 12% required re-treatment at 2 years.